Novanta Reports Strong Q3 2026 Results Driven by Medical Segment and Riverpoint Acquisition
Novanta Inc. (NOVT) delivered robust third-quarter 2026 financial results, reporting revenue of $305 million, a 23.1% increase year-over-year. The company's growth was bolstered by its strategic shift toward medical end markets, which now account for 53% of total sales, and the successful integration of Riverpoint Medical following its July acquisition. Despite strong top-line performance and record adjusted EBITDA margins of 26.3%, management noted specific headwinds. These include production slowdowns at the Stockport facility in the U.K. affecting fourth-quarter gross margins and ongoing supply chain tightness regarding rare earth materials and electronic components. Looking ahead, Novanta provided optimistic guidance for 2027, projecting revenue growth exceeding 15%.
Tickers: $NOVT
Topics: acquisition_performance adjusted_ebitda customer_bookings eps revenue growth